Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00123565 · ClinicalTrials.gov registry record · Phase 2
Hexadecasaccharide (SR123781A) in Patients With Unstable Angina or Non-ST-Segment Elevation Myocardial Infarction
A Phase 2 study, sponsored by Sanofi.
- Completed
- Registry status
- Phase 2
- Development phase
- 1,257
- Enrollment target
NCT00123565: Completed Phase 2 study, sponsored by Sanofi.
NCT00123565 is a Phase 2 study that has completed, run by Sanofi. The registered enrollment target is 1,257 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (845% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00123565, a Phase 2 study, has completed, sponsored by Sanofi.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 1,257 participants
- Enrollment target
Study Summary
The purpose of this study is to test whether SR123781A is a possible treatment for patients with acute coronary syndromes (heart attack) who are scheduled to undergo a percutaneous coronary intervention (PCI) within 48 hours after inclusion in the study. Two doses of SR123781A are currently tested, each in a group of about 180 patients per group to find which is the most adequate, versus heparin and glycoprotein IIbIIIa (GPIIBIIIA) antagonist.
Interventions
- DRUG Hexadecasaccharide (SR123781A)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,257 participants |
| Start Date | 2004-12 |
| Est. Completion | 2007-05 |
| Phase | Phase 2 |
What the finished NCT00123565 record still lists
NCT00123565 is an interventional study that assigns participants to a tested intervention. Its 1,257 participants enrollment target places it among the larger protocols in the corpus, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (845% higher).
The record links to 0 conditions, and to 1 intervention - of which Hexadecasaccharide (SR123781A) is the first listed.
NCT00123565 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00123565 about?
NCT00123565 is a clinical study titled "Hexadecasaccharide (SR123781A) in Patients With Unstable Angina or Non-ST-Segment Elevation Myocardial Infarction". The purpose of this study is to test whether SR123781A is a possible treatment for patients with acute coronary syndromes (heart attack) who are scheduled to undergo a percutaneous coronary intervention (PCI) within 48 hours after inclusion in the study. Two doses of SR123781A are currently tested, ...
What is the current status of trial NCT00123565?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 1,257 participants. The study started on 2004-12. Estimated completion is 2007-05.
What interventions are being tested in trial NCT00123565?
The interventions under investigation include: Hexadecasaccharide (SR123781A) (DRUG).
Who is sponsoring clinical trial NCT00123565?
This trial is sponsored by Sanofi, which has 713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00123565's enrollment target sits among peer trials
1,257 16th of 2000 higher than 1,985 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06712316 · 1,260 participants · Phase 2
Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer
- NCT06812273 · 1,260 participants · NA
Mediators and Moderators of Auditory Training
- NCT06931340 · 1,260 participants · Phase 3
Testing the Addition of Docetaxel (Chemotherapy) to the Usual Treatment (Hormonal Therapy and Apalutamide) for Metastatic Prostate Cancer, ASPIRE Trial
- NCT06119581 · 1,264 participants · Phase 3
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia